REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Recruiting · NCT06875986 · Observational (researchers observe without assigning treatment) · Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
Brexpiprazole (Rexulti)
What this trial is about
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Who can take part
Age range
15 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients diagnosed with Alzheimer's disease
Where it is running
1 location listed.
- Pharmacovigilance Department - Osaka, Osaka, Japan